Right ventricular and right atrial function and deformation in patients with subclinical hypothyroidism: a two- and three-dimensional echocardiographic study

Marijana Tadic¹, Sanja Ilic² and Vera Celic¹,³

¹Cardiology Department and ²Department of Endocrinology, University Clinical Hospital Center ‘Dr Dragisa Misovic’, Heroja Milana Tepica 1, 11000 Belgrade, Serbia and ³Faculty of Medicine, Doktora Subotica 6, 11000 Belgrade, Serbia

Abstract

Background: We sought to investigate right ventricular (RV) function and deformation assessed by three-dimensional echocardiography (3DE) and speckle tracking in patients with subclinical hypothyroidism (SHT), and to evaluate the influence of levothyroxine (L-T₄) therapy on RV remodeling.

Methods: We included 50 untreated women with SHT and 45 healthy control women matched by age. The L-T₄ therapy was prescribed to all SHT patients who were followed 1 year after euthyroid status was achieved. All study participants underwent laboratory analyses which included thyroid hormone levels, and complete two-dimensional echocardiography (2DE) and 3DE examinations.

Results: 3DE RV end-diastolic volume and ejection fraction were significantly reduced in the SHT patients before therapy in comparison with the healthy controls and treated SHT subjects. RV longitudinal strain, systolic, and early diastolic strain rates (SRs) were significantly decreased, whereas RV late diastolic SR was increased in the SHT patients before therapy when comparing with the controls. 2DE speckle tracking imaging revealed that L-T₄ substitution therapy significantly improved RV systolic mechanics, whereas RV diastolic deformation was not completely recovered. Right atrial (RA) function and deformation were significantly impacted by SHT. Replacement L-T₄ treatment improved but did not completely restore RA mechanics in the SHT patients.

Conclusion: RV and RA function and mechanics are significantly affected by SHT. L-T₄ therapy and 1-year maintenance of euthyroid status improved but did not completely recover RV and RA function and deformation in the SHT patients, which implies that right heart remodeling caused by SHT is not reversible in a 1-year period.

Introduction

The cardiovascular system represents one of the most prominent targets of thyroid hormones, which is easily detected in overt hyper- or hypothyroidism (1). The influence of subclinical thyroid dysfunction on the heart and the cardiovascular system is significantly less studied, and pathophysiological mechanisms of this relationship are still unclear (2). Studies showed that subclinical hypothyroidism (SHT) is associated with left ventricular remodeling, especially hypertrophy and diastolic dysfunction (3, 4, 5, 6, 7, 8). However, the influence of SHT on the right ventricle (RV), as well as the effect of levothyroxine (L-T₄) therapy on RV remodeling, has been investigated in several studies which used only pulsed and tissue Doppler for the estimation of RV function (9, 10, 11, 12, 13, 14).
To our knowledge, there is no study which used three-dimensional echocardiography (3DE) and two-dimensional (2DE) speckle tracking imaging for assessment of RV function and mechanics in the SHT patients. Additionally, right atrial (RA) mechanics in the SHT patients have not been evaluated so far.

The aim of our investigation was to determine RV and RA function and deformation in the SHT patients, and to evaluate the effect of substitution L-T₄ therapy on RV and RA remodeling in these patients using 3DE and 2DE speckle tracking imaging.

**Methodology**

Our study enrolled 50 female patients with untreated SHT and 45 age-matched healthy female volunteers. The study was conducted at the Endocrinology and Cardiology Department, University Clinical Hospital Center ‘Dr Dragisa Misovic’ in Belgrade, Serbia, between January 2010 and June 2013. The etiology of SHT in all the patients was chronic autoimmune thyroiditis, which was diagnosed by increased circulating antiperoxidase and/or anti-thyroglobulin autoantibodies and diffuse hypoechogenicity by thyroid ultrasound. The inclusion criteria were age (≤50 years) and increased serum TSH level with normal levels of free tri-iodothyronine (FT₃) and free thyroxine (FT₄). Subjects with symptoms or signs of cardiovascular disease (arterial hypertension, myocardial infarction, atrial fibrillation, heart failure, congenital heart disease, valvular disease), obesity (BMI ≥30 kg/m²), asthma, chronic obstructive lung disease, neoplastic disease, cirrhosis of the liver, kidney failure, sleeping disorders, or type 2 diabetes mellitus, as well as professional athletes, were excluded from the study.

Anthropometric measures (height, weight) and laboratory analyses (level of thyroid hormones, total cholesterol, LDL and HDL cholesterol, triglycerides) were taken from all the subjects included in the study. Data about smoking habits, family history of coronary artery disease (CAD), asthma, and obstructive pulmonary disease were taken from all study subjects. Fasting venous blood samples were drawn between 0800 and 0900 h. None of the participants used any medication before their inclusion into the study. Normal ranges for FT₃, FT₄, and TSH, were 1.5–4.1 pg/ml, 11.5–22.7 pmol/l, and 0.4–4 mIU/l respectively. FT₃ level was determined by IMMULITE 1000, a competitive analog-based immunoassay; FT₄ level was assessed by IMMULITE 2000 enzyme–labeled chemiluminescent competitive immunoassay; and TSH level was determined by using IMMULITE 2000, third generation two-site chemiluminescent immunometric assay.

After the baseline assessment, the patients with SHT were assigned to receive L-T₄ replacement, starting with 25 μg/day. TSH was measured every 8 weeks in order to adjust the dose. Euthyroid state was achieved with a mean dose of 74 μg/day in 18.2 ±5.3 weeks. Echocardiographic examination was performed before starting the treatment and 1 year after euthyroid state had been achieved by L-T₄ treatment. BMI and body surface area (BSA) were calculated for each patient. The study was approved by the local ethics committee and informed consent was obtained from all the participants.

**Echocardiography**

Echocardiographic examination was performed by using a 2.5 MHz transducer with a harmonic capability of a Vivid 7 ultrasound machine (GE Healthcare, Horten, Norway).

**Standard 2DE examination**

The values of all 2DE parameters were obtained as the average value of three consecutive cardiac cycles. The LV end-systolic and end-diastolic diameters (LVEDD), the left ventricle posterior wall (PWT), and interventricular septum thickness were determined according to the current recommendations (15). Relative wall thickness was calculated as (2×PWT)/LVEDD. Left ventricular ejection fraction (EF) was estimated by using the biplane method. Left ventricular mass was calculated using the Devereux formula (16) and indexed for height powered to 2.7.

Transmitral Doppler inflow and tissue pulsed Doppler were obtained in the apical four-chamber view. Pulsed Doppler measurements included the transmitral early diastolic peak flow velocity (E), late diastolic flow velocity (A), and their ratio (E/A) (17).

**RV and atrium**

The RV internal end-diastolic diameter was measured in M-mode in the parasternal long-axis view (18). RV end-diastolic thickness was measured in the subcostal view (18). The RV fractional area change (RV FAC) was measured from the apical four-chamber view. RV FAC was calculated using the formula: (end-diastolic area–end-systolic area)/end-diastolic area (18). The RA transverse and longitudinal diameters were measured in the apical four-chamber view at the ventricular end-systole (18). RA areas and volumes were obtained by using the biplane method of discs formula (18). RA EF was...
calculated as \((RA\text{ volume maximum } – RA\text{ volume minimum})/RA\text{ volume maximum}\).

Tricuspid flow velocities were achieved by the standard pulsed wave Doppler technique in the apical four-chamber view. The following parameters were determined: early diastolic peak flow velocity \((E_t)\), late diastolic flow velocity \((A_t)\), their ratio \((E/A_t)\), and \(E_t\) velocity deceleration time \((DT_t)\). Tissue Doppler imaging was used to obtain the RV myocardial velocities in the apical four-chamber view with a sample volume placed at the lateral segment of the tricuspid annulus during early diastole \((e')\) and systole \((s_t)\) \((18)\). \((E/e')\), ratio of the RV was determined by using previously estimated Doppler values.

RV global systolic function was assessed as the tricuspid annular plane systolic excursion (TAPSE), which was measured as the difference between the distance among the tricuspid annulus and RV apex at the end-diastole and end-systole of the same cardiac cycle \((18)\).

The parameters necessary for the calculation of the Tei index of the RV were obtained by the tissue Doppler in the apical four-chamber view, according to specific guidelines \((18, 19)\).

Assessment of the RV systolic or diastolic dysfunction, along with the global function, was based on the current recommendations \((18)\). RV systolic blood pressure (RVSP) was assessed in a subset of patients with minimal/mild tricuspid regurgitation.

**Two-dimensional strain and strain rate**

2DE strain imaging was performed by using three consecutive cardiac cycles of 2DE images in the apical four-chamber view at the end of expiration \((18)\). The frame rate ranged between 60 and 80 frames/s. Commercially available software EchoPAC 110.1.2, GE Healthcare, was used for the 2DE strain analysis. The variables which were used for evaluation of systolic function and contractility were the longitudinal peak and systolic strain rate (SR) respectively. Parameters of early myocardial relaxation and late ventricular filling were estimated by early and late diastolic SR. We estimated peak longitudinal strain, systolic and diastolic SRs for the RV, and interventricular septum separately.

The RA speckle tracking analysis was done after the endocardial border was manually traced in the four-chamber view. Six longitudinal strain curves were generated by the software for each atrial segment. RA peak atrial longitudinal strain was calculated by averaging values observed in all RA segments. RA peak systolic SR was measured at RV systolic phase, while early and late RA SRs were measured during early RV filling and throughout late RV diastolic phase respectively.

**3DE acquisition**

A full-volume acquisition of the RV required for further analyses was obtained by harmonic imaging from an apical approach. Six electrocardiogram-gated consecutive beats were acquired during end-expiratory breath-hold to generate full volume. All data sets were stored digitally and analyzed by the commercially available software, RV TomTec (EchoPAC 110.1.2, GE Healthcare), which was used for the off-line analysis of RV volumes, stroke volume, and EF. Frame rates were between 20 and 30 frames/s.

**Statistical analysis**

Continuous variables were presented as mean \(\pm\) s.d. and were compared by using the two-tailed Student’s \(t\)-test as they showed normal distribution. Comparisons between the controls and the patients were performed by an independent-samples \(t\)-test. The data before and after \(\text{L-T}_4\) therapy were compared by a paired-samples \(t\)-test. The differences in TSH levels presented as median values were analyzed using the Mann–Whitney \(U\) test or Wilcoxon test. The differences in proportions were compared by using the \(\chi^2\)-test. The correlations were determined by the Pearson rank correlation test. The \(P\) value \(<0.05\) was considered statistically significant.

**Results**

Basic demographic characteristics and clinical parameters of the study population are presented in Table 1. There were no differences in the prevalence of smoking, family history of CADs, or obstructive pulmonary disease between the two groups (Table 1). The controls and the SHT patients did not differ in age, BMI, BSA, heart rate, or blood pressure. As it is expected, FT\(_3\) and FT\(_4\) level were similar between the controls and the SHT participants (before and after substitution therapy), whereas TSH was significantly higher in the SHT patients at baseline in comparison with the controls or values after treatment (Table 1). Triglyceride level and HDL cholesterol were similar between healthy volunteers and the SHT patients. On the other hand, total cholesterol and LDL cholesterol progressively decreased from the SHT patients before therapy, amongst the SHT patients after therapy, to the controls.
2DE left ventricular and atrial parameters

Left ventricular diameters were similar between the controls and the SHT patients. Interventricular septum thickness and relative wall thickness were increased in the SHT patients at baseline in comparison with the controls (Table 2). The left atrial diameter was similar between the observed groups. The LV mass index was increased in the SHT patients at baseline in comparison with the controls and the SHT patients after therapy. LV EF was similar between the groups. Transmitral E/A ratio was significantly decreased in the SHT patients before therapy compared with the controls and the SHT patients after therapy (Table 2).

2DE RV and atrial parameters

RV and RA diameters, as well as RV end-systolic and end-diastolic areas, were similar among the groups (Table 2). The RV thickness was increased in the SHT patients at baseline in comparison with the controls and the treated patients. The RA volumes were higher in untreated SHT participants than in the controls. The RA EF was lower in the SHT patients before therapy than in the controls or the treated SHT patients (Table 2).

Transticuspid E/A ratio is significantly decreased, and E/e₀ ratio is significantly increased, in the SHT patients in comparison with controls and the SHT patients after therapy (Table 2). Parameters of the RV systolic function such as TAPSE and s_t were similar between the observed groups. However, the Tei index, an indicator of the RV global function, is significantly increased in the SHT patients at baseline compared with healthy controls and the treated participants (Table 2).

3DE RV parameters

The RV end-diastolic and stroke volumes are significantly lower in untreated SHT patients in comparison with the controls and the SHT subjects after l-T₄ therapy (Table 2). Interestingly, end-systolic RV volume was similar between the observed subjects. These hemodynamic changes result in lower 3DE RV EF among untreated SHT subjects (Table 2).

RV and atrial function: two-dimensional speckle tracking imaging

The global RV and interventricular septum longitudinal strain were decreased in the SHT subjects before the substitution therapy as opposed to the controls, but similar with treated SHT patients (Table 3). Systolic RV SR was decreased in untreated SHT patients in comparison with the controls and treated subjects. Early diastolic RV SR was significantly increased, whereas late diastolic RV SR was significantly decreased, in the controls compared with the SHT patients (before and after therapy).

### Table 1  Demographic characteristics and clinical parameters of study population.

<table>
<thead>
<tr>
<th></th>
<th>Controls (n = 45)</th>
<th>Baseline SHT (n = 50)</th>
<th>SHT after 12 months (n = 50)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>38 ± 7</td>
<td>40 ± 6</td>
<td>–</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>24.4 ± 4</td>
<td>24.7 ± 4.6</td>
<td>24.5 ± 4.4</td>
</tr>
<tr>
<td><strong>BSA (m²)</strong></td>
<td>1.71 ± 0.18</td>
<td>1.73 ± 0.15</td>
<td>1.70 ± 0.17</td>
</tr>
<tr>
<td><strong>Smoking (%)</strong></td>
<td>14 (31)</td>
<td>14 (28)</td>
<td>–</td>
</tr>
<tr>
<td><strong>Positive family history of coronary artery disease (%)</strong></td>
<td>7 (15)</td>
<td>9 (18)</td>
<td>–</td>
</tr>
<tr>
<td><strong>Positive family history of asthma or COPD (%)</strong></td>
<td>3 (7)</td>
<td>4 (8)</td>
<td>–</td>
</tr>
<tr>
<td><strong>Heart rate (beats/min)</strong></td>
<td>71 ± 12</td>
<td>70 ± 11</td>
<td>72 ± 10</td>
</tr>
<tr>
<td><strong>Clinic systolic BP (mmHg)</strong></td>
<td>122 ± 8</td>
<td>123 ± 9</td>
<td>122 ± 9</td>
</tr>
<tr>
<td><strong>Clinic diastolic BP (mmHg)</strong></td>
<td>73 ± 8</td>
<td>72 ± 9</td>
<td>74 ± 7</td>
</tr>
<tr>
<td><strong>FT₃ (pmol/l)</strong></td>
<td>2.5 ± 0.7</td>
<td>2.47 ± 0.53</td>
<td>2.6 ± 0.58</td>
</tr>
<tr>
<td><strong>FT₄ (pmol/l)</strong></td>
<td>14.5 ± 2.5</td>
<td>14.2 ± 2.1</td>
<td>14.7 ± 2.9</td>
</tr>
<tr>
<td><strong>TSH (mIU/ml)</strong></td>
<td>2.23 ± 0.8*</td>
<td>8.23 ± 2.11*</td>
<td>2.07 ± 0.75*</td>
</tr>
<tr>
<td><strong>TSH (median (range)) (mIU/ml)</strong></td>
<td>2.1 (0.8–3.8)*</td>
<td>8.1 (5.1–11)*</td>
<td>2 (0.7–3.4)*</td>
</tr>
<tr>
<td><strong>Triglycerides (mmol/l)</strong></td>
<td>1.21 ± 0.68</td>
<td>1.33 ± 0.66</td>
<td>1.28 ± 0.65</td>
</tr>
<tr>
<td><strong>Total cholesterol (mmol/l)</strong></td>
<td>4.58 ± 0.74*</td>
<td>5.44 ± 0.92*</td>
<td>5.09 ± 0.8*</td>
</tr>
<tr>
<td><strong>LDL cholesterol (mmol/l)</strong></td>
<td>2.6 ± 0.59*</td>
<td>3.3 ± 0.7*</td>
<td>3 ± 0.63*</td>
</tr>
<tr>
<td><strong>HDL cholesterol (mmol/l)</strong></td>
<td>1.52 ± 0.27</td>
<td>1.44 ± 0.24</td>
<td>1.47 ± 0.25</td>
</tr>
</tbody>
</table>

BSA, body surface area; BP, blood pressure; COPD, chronic pulmonary disease; FT₃, free tri-iodothyronine; FT₄, free thyroxine; TSH, thyroid-stimulating hormone; SHT, subclinical hypothyroidism. *P < 0.01 for controls vs baseline, †P < 0.01 for controls vs SHT after 12 months, ‡P < 0.05 for baseline vs SHT after 12 months, §P < 0.01 for baseline vs SHT after 12 months.
Before therapy compared with the controls (Table 3).

In the whole study population, which includes the controls and the SHT patients before and after L-T4 therapy, Interventricular septum SRs differ only between untreated SHT subjects and the controls (Table 3). The global RA strain is decreased in the SHT patients before therapy compared with the controls (Table 3). Similar results are obtained for RA SRs. Namely, systolic and early diastolic SRs are increased, whereas late diastolic SR is decreased, in the controls compared with the SHT patients (before and after therapy). On the other hand, the difference between untreated and treated SHT patients in RA strain and SRs is statistically insignificant.

### Correlation and regression analyses

In the whole study population, which includes the controls and the SHT patients before and after L-T4 therapy, TSH level correlated with RV wall thickness (r = 0.38, P < 0.01), E/A1 ratio (r = −0.34, P = 0.01), E/e1 (r = 0.36, P < 0.01), RV Tei index (r = −0.4, P < 0.01), 3DE RV EF (r = −0.45, P < 0.01), RV global longitudinal strain (r = −0.47, P < 0.01) and RA global longitudinal strain (r = −0.42, P < 0.01). However, after adjustment for LV mass index and RV wall thickness, TSH level was associated only with the RV Tei index (β = −0.32, P = 0.02), 3DE RV EF (β = −0.38, P < 0.01), and RV longitudinal strain (β = −0.41, P < 0.01).

### Discussion

Our study revealed several new findings: i) RV function assessed by 3DE is deteriorated in the SHT subjects; ii) RV mechanics evaluated by 2DE strain is significantly...
impairment in the SHT patients; iii) RA mechanics is also changed in SHT; iv) thyroxine therapy significantly improved RV and RA function and mechanics, but right heart remodeling is not completely reversible even after 1 year of euthyroid status.

The relationship between right heart and SHT is intriguing, and despite the fact that several studies showed an association between RV remodeling and this kind of thyroid dysfunction (9, 10, 11, 12, 13), the pathophysiological explanation and mechanisms are still under debate. At the molecular level, this relationship could be illuminated in several ways. First, altered management of intracellular calcium (20, 21); second, changed myocardial fiber orientation and capillary blood flow distribution (22, 23); third, reduced cardiac oxygen consumption which is associated with increased peripheral resistance, reduced contractility, and decreased efficiency (24); fourth, decreased degradation of myocardial matrix and increased insulin growth factor 1 which might induce cardiac hypertrophy and further RV dysfunction (25, 26); and fifth, dyslipidemia, found also in our investigation, could have an influence on cardiac remodeling (27). An important mechanism which should also be mentioned is increased pulmonary vascular resistance and pulmonary hypertension in SHT patients. Namely, studies showed increased prevalence of hypothyroidism in patients with pulmonary hypertension (28), which aroused the suspicion about an autoimmune pathogenetic link between pulmonary hypertension and hypothyroidism (29). Finally, the ventricular interaction could also be a cornerstone of RV remodeling in SHT in two ways: firstly, through the interventricular septum (30), which transduces pressure and volume overload from the left ventricle to RV; and secondly, by transmission of increased left ventricular filling pressure through the pulmonary vascular bed to the RV.

The 2DE assessment of the RV is very challenging due to complicated RV architecture that makes it insufficiently accessible for 2DE examination. The introduction of 3DE enables the accurate quantitation of RV volumes, function, and mass, and this accuracy can be compared with the results of MRI, which still remains a gold standard for the RV evaluation (31, 32). Additionally, 2DE speckle tracking imaging, unlike conventional tissue Doppler imaging, identifies RV and RA myocardial deformation during the whole cardiac cycle, providing information not only about global strain but regional as well, and it also represents a highly reproducible imaging tool which could easily be used in everyday clinical practice (33).

Our study showed that RV diastolic function was impaired in the SHT patients, which agrees with previous investigations (9, 10, 11, 12, 13). The impact of SHT on RV systolic function is more controversial. Our findings revealed that RV systolic function estimated by 3DE and

Table 3  Echocardiographic parameters of right ventricular function (2D strain) in the study population.

<table>
<thead>
<tr>
<th></th>
<th>Controls (n=45)</th>
<th>Baseline SHT (n=50)</th>
<th>SHT after 12 months (n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2DE RV strain and strain rates</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Longitudinal RV strain (%)</td>
<td>−29 ± 6¹</td>
<td>−26 ± 5¹</td>
<td>−28 ± 5</td>
</tr>
<tr>
<td>Septum</td>
<td>−24 ± 5*</td>
<td>−22 ± 4*</td>
<td>−23 ± 4</td>
</tr>
<tr>
<td><strong>RV systolic strain rate (per second)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global RV</td>
<td>−1.83 ± 0.44¹</td>
<td>−1.52 ± 0.41³,⁵</td>
<td>−1.69 ± 0.42⁵</td>
</tr>
<tr>
<td>Septum</td>
<td>−1.65 ± 0.4¹</td>
<td>−1.4 ± 0.31¹</td>
<td>−1.53 ± 0.38</td>
</tr>
<tr>
<td><strong>RV early diastolic strain rate (per second)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global RV</td>
<td>1.9 ± 0.41¹,⁵</td>
<td>1.6 ± 0.45¹</td>
<td>1.72 ± 0.42¹</td>
</tr>
<tr>
<td>Septum</td>
<td>1.76 ± 0.36¹</td>
<td>1.5 ± 0.4³</td>
<td>1.64 ± 0.38</td>
</tr>
<tr>
<td><strong>RV late diastolic strain rate (per second)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global RV</td>
<td>1.46 ± 0.33¹,⁸</td>
<td>1.72 ± 0.36¹</td>
<td>1.6 ± 0.42⁵</td>
</tr>
<tr>
<td>Septum</td>
<td>1.41 ± 0.3¹</td>
<td>1.64 ± 0.35¹</td>
<td>1.52 ± 0.33</td>
</tr>
<tr>
<td><strong>2DE RA strain and strain rate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Longitudinal RA strain (%)</td>
<td>46 ± 7¹</td>
<td>42 ± 6¹</td>
<td>44 ± 6</td>
</tr>
<tr>
<td>RA systolic strain rate (per second)</td>
<td>2.2 ± 0.6*</td>
<td>1.95 ± 0.56*</td>
<td>2.08 ± 0.62</td>
</tr>
<tr>
<td>RA early diastolic strain rate (per second)</td>
<td>−2.43 ± 0.72*</td>
<td>−2.12 ± 0.65*</td>
<td>−2.3 ± 0.66</td>
</tr>
<tr>
<td>RA late diastolic strain rate (per second)</td>
<td>−2.0 ± 0.6*</td>
<td>−2.28 ± 0.67*</td>
<td>−2.08 ± 0.62</td>
</tr>
</tbody>
</table>

RA, right atrium; RV, right ventricle. *P<0.05 for controls vs baseline SHT, †P<0.01 for controls vs baseline, ‡P<0.05 for controls vs SHT after 12 months, §P<0.05 for baseline vs SHT after 12 months.
2DE speckle tracking imaging was significantly deteriorated in the SHT participants, which was not found previously by using conventional echocardiographic tools (9, 10, 11, 12, 13, 14). However, Ripoli et al. (34) using cardiac MRI showed that SHT individuals had significantly reduced cardiac preload and increased afterload with a consequent decrease in stroke volume and cardiac output, which concurs with our results about the RV. Our results also could be a consequence of increased RV wall thickness among the SHT patients before L-T4 therapy, which was also found by Kosar et al. (35) in clinical hypothyroid patients.

This study revealed that RV and RA deformation is significantly impacted by SHT, which is a new finding. We would like to emphasize that RV systolic SR which indicates RV systolic deformation was decreased in the SHT patients at baseline in comparison with the controls and treated SHT patients; however, RV early and late diastolic SRs were similar between untreated and treated SHT patients, but significantly deteriorated compared with the controls. These results imply that L-T4 therapy improved RV systolic and diastolic function, but the improvement is not complete. In other words, RV remodeling in SHT is not completely reversible even after L-T4 therapy and maintenance of euthyroid status for a year. Other authors showed that replacement therapy resulted in rapid and complete improvement of primarily RV diastolic function (9, 10), but we should be aware of the fact that these authors did not use techniques which could detect subtle changes in cardiac function. Our results show that RV systolic function, estimated by 3DE RV EF, RV global systolic strain, and SRs, was completely restored after L-T4 therapy; whereas RV diastolic function, assessed by RV early and late diastolic SRs, apparently needs more time for improvement. Interestingly, the interventricular septum does not completely follow RV changes in our SHT patients because the difference in deformation exists only between the healthy controls and the SHT patients at baseline, whereas its function after replacement therapy is improved and is not significantly different from the controls. In fact, the difference is between the controls and the SHT patients at baseline. This means that the interventricular septum and left ventricle recover sooner than the RV which is important in determining the duration of treatment in SHT. Furthermore, even after restoration of RV wall thickness in treated SHT patients, RV mechanics have not been completely recovered, which questions the unfavorable influence of RV hypertrophy on RV function in SHT.

The RA function and deformation in SHT has not been evaluated before. Gaynor et al. (36) previously emphasized the importance of RA three-phasic function: reservoir, conduit, and booster pump function. Our results revealed that systolic and diastolic RA function estimated by 2DE strain are significantly impaired in SHT, which only contributes to the development of RV dysfunction in these patients. This study also showed that 2DE RA EF was reduced in the SHT patients at baseline. Additionally, L-T4 therapy improved RA function and mechanics, but still not enough to reach the function of the healthy control subjects.

Limitations
This study has several limitations. Firstly, 3DE estimation of RV structure and function might be significantly influenced by the quality of echocardiographic images, especially during the full-volume acquisition. Secondly, our investigation included only women, which restricts our results to this population. On the other hand, SHT is mostly seen in females, which is why we decided to include only women. Thirdly, the existence of CAD was not excluded by coronary angiography, but we included young females without cardiovascular risk factors, thus expected prevalence of CAD in this population is very low.

Conclusion
The RV function and deformation assessed by 3DE and 2DE strains are significantly deteriorated in the SHT subjects. One-year L-T4 therapy improved, but did not completely restore RV and RA myocardial function and deformation. This implies that longer substitution therapy is necessary for complete repair of the right heart in SHT patients. Prospective studies are needed to confirm the negative influence of SHT on RV remodeling, as well as to assess the effect of these impairments on morbidity and mortality in this population. Further longitudinal studies are also required to evaluate the effect of L-T4 replacement therapy on RV remodeling and to define the duration of treatment which is needed for the complete recovery of cardiac function in SHT.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.


20 Dillmann WH. Biochemical basis of thyroid hormone action in the heart. American Journal of Medicine 1999 88 626–632. (doi:10.1016/s0002-9343(99)90530-0)

21 Ojamaa K & Klein I. In vivo regulation of recombinant cardiac myosin heavy chain gene expression by thyroid hormone. Endocrinology 1993 132 1002–1010. (doi:10.1210/endo.132.3.1002)


29 Badescu DB, Wynne KM, Bournazol S, Voelkel NF, Ridgway C & Groves BM. Hypothyroidism and primary pulmonary hypertension: an


Received 18 August 2013
Revised version received 30 September 2013
Accepted 10 October 2013